HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.

Weight loss with tirzepatide was fairly uniform across different body mass index (BMI) ranges, ages, and number of obesity-related comorbidities in patients with overweight/obesity without type 2 ...

Tirzepatide is associated with longer continuous glycemic control than placebo or active comparators in type 2 diabetes (T2D). These findings, from a post hoc analysis, were published in Diabetes ...

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to three years,” Dr. Busetto noted. He added, “Regardless of age, BMI, and ...

Popular weight loss drugs such as Wegovy and Zepbound have shown incredible success in clinical trials. But in the real world, patients might not lose as much weight—here's why.

Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the U.S. Food and Drug Administration.

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...